Singapore, March 21 -- Merck invests more than €300 million into a new Bioprocessing Production Centre in Daejeon, South Korea. The new site is the largest investment by the company's Life Science business sector in Asia-Pacific to date and demonstrates its commitment to expanding its capacities in the fast-growing region.

The investment is expected to create approximately 300 additional jobs by the end of 2028. The facility will support biotechnology and pharmaceutical companies in process development, clinical research and commercial manufacturing of biologics.

Biologics are derived from large and complex biological compounds and include products like vaccines, cell and gene therapies, or protein-based therapies, such as monoclo...